Journal of computer-aided molecular design
Nov 4, 2025
Evolution has optimized proteins over time by the incorporation of precise and context-specific amino acid substitutions adapted to structural and functional demands. We have reconceptualized this principle using deep learning to engineer monoclonal ...
Cell-to-cell communication through ligand-receptor (LR) interactions can fundamentally shape the tumor microenvironment and immune responses, but the full spectrum of these interactions in anti-PD-1 therapy remains unexplored. We developed a predicti...
BACKGROUND: Anti-programmed cell death-1 (PD-1) immunotherapy and platinum-based chemotherapy are key components of first-line treatment for advanced Gastric or Gastroesophageal Junction (G/GEJ) cancer. However, the role of immune cells infiltrating ...
BMC medical informatics and decision making
Aug 8, 2025
BACKGROUND: Anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunotherapy has revolutionized cancer treatment. However, it can cause immune-related adverse events, including acute kidney injury (AKI). Such adverse e...
BACKGROUND: PD-1/PD-L1 immunotherapy represents the primary treatment for advanced NSCLC patients; however, response rates to this therapy vary among individuals. This dual-center study aimed to integrate habitat radiomics and multi-instance deep lea...
INTRODUCTION: Colorectal cancer (CRC), the third most common cancer worldwide, often shows limited responsiveness to immunotherapy due to its predominantly immune-excluded phenotype. Despite increasing insights into the complex tumor microenvironment...
The global burden of cancer continues to grow, posing a significant public health challenge. Although cancer immunotherapy has shown significant efficacy, the response rate is not high. Therefore, the objective of our research was to identify the lat...
Immunopharmacology and immunotoxicology
Nov 22, 2024
BACKGROUND: Immune checkpoint inhibitors (ICIs) show promise in cancer treatment but can lead to immune-related adverse events (irAEs), notably affecting the skin. Understanding the factors behind these skin reactions is crucial for effective managem...
International journal of biological macromolecules
Oct 15, 2024
Molecular design of small-molecule inhibitors targeting programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway has been recognized as an active research area by the clinical success of cancer immunotherapy. In recent years, usi...
BACKGROUND: Immune checkpoint inhibitor (ICI) has been widely used in the treatment of advanced cancers, but predicting their efficacy remains challenging. Traditional biomarkers are numerous but exhibit heterogeneity within populations. For comprehe...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.